JP2015096065A5 - - Google Patents

Info

Publication number

JP2015096065A5

JP2015096065A5 JP2014231997A JP2014231997A JP2015096065A5 JP 2015096065 A5 JP2015096065 A5 JP 2015096065A5 JP 2014231997 A JP2014231997 A JP 2014231997A JP 2014231997 A JP2014231997 A JP 2014231997A JP 2015096065 A5 JP2015096065 A5 JP 2015096065A5

Authority

JP

Japan

Prior art keywords

conjugate

tumor

seq

chain variable

plvap

Prior art date

2014-11-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 36
• 101000620348 Homo sapiens Plasmalemma vesicle-associated protein Proteins 0.000 claims description 25
• 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 claims description 24
• 210000005166 vasculature Anatomy 0.000 claims description 20
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
• 210000004027 cell Anatomy 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 102000004169 proteins and genes Human genes 0.000 claims description 15
• 108090000623 proteins and genes Proteins 0.000 claims description 15
• 239000002246 antineoplastic agent Substances 0.000 claims description 14
• 229940127089 cytotoxic agent Drugs 0.000 claims description 14
• 102000002262 Thromboplastin Human genes 0.000 claims description 12
• 108010000499 Thromboplastin Proteins 0.000 claims description 12
• 238000011282 treatment Methods 0.000 claims description 10
• 208000007536 Thrombosis Diseases 0.000 claims description 8
• 206010054094 Tumour necrosis Diseases 0.000 claims description 8
• 210000001367 artery Anatomy 0.000 claims description 6
• 108020004707 nucleic acids Proteins 0.000 claims description 6
• 102000039446 nucleic acids Human genes 0.000 claims description 6
• 150000007523 nucleic acids Chemical class 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 5
• 239000000203 mixture Substances 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
• 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
• 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
• 229960000397 bevacizumab Drugs 0.000 claims description 4
• 210000004899 c-terminal region Anatomy 0.000 claims description 4
• 238000000315 cryotherapy Methods 0.000 claims description 4
• 230000001939 inductive effect Effects 0.000 claims description 4
• 238000002347 injection Methods 0.000 claims description 4
• 239000007924 injection Substances 0.000 claims description 4
• 230000002601 intratumoral effect Effects 0.000 claims description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
• 238000007674 radiofrequency ablation Methods 0.000 claims description 4
• 238000001959 radiotherapy Methods 0.000 claims description 4
• 229960003787 sorafenib Drugs 0.000 claims description 4
• 238000001356 surgical procedure Methods 0.000 claims description 4
• 108060003951 Immunoglobulin Proteins 0.000 claims description 3
• 230000001580 bacterial effect Effects 0.000 claims description 3
• 102000018358 immunoglobulin Human genes 0.000 claims description 3
• 229940124597 therapeutic agent Drugs 0.000 claims description 3
• 241000238631 Hexapoda Species 0.000 claims description 2
• 241000124008 Mammalia Species 0.000 claims description 2
• 239000002872 contrast media Substances 0.000 claims description 2
• 239000002552 dosage form Substances 0.000 claims description 2
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 230000006698 induction Effects 0.000 claims description 2
• 210000004962 mammalian cell Anatomy 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
• 238000004519 manufacturing process Methods 0.000 claims 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
• 101710102828 Vesicle-associated protein Proteins 0.000 claims 1
• 210000004102 animal cell Anatomy 0.000 claims 1
• 230000002538 fungal effect Effects 0.000 claims 1
• 239000012528 membrane Substances 0.000 claims 1
• 238000000034 method Methods 0.000 description 20
• 230000015271 coagulation Effects 0.000 description 11
• 238000005345 coagulation Methods 0.000 description 11
• 239000000701 coagulant Substances 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 241000235343 Saccharomycetales Species 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 102000054625 human PLVAP Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1